You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lenvima

Showing 1 - 25 of 120
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 13, 2023

GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))

Not yet recruiting
  • GBM
  • (no location specified)
Aug 2, 2023

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Overall Survival in Unresectable Hepatocellular Carcinoma

Completed
  • Carcinoma, Hepatocellular
  • +3 more
  • Osaka, Japan
  • +1 more
Mar 7, 2022

Refractory Tumor, Solid Tumor Trial in Kaohsiung, Tainan (Dendritic Cell Vaccine, Lenvatinib, Nivolumab)

Not yet recruiting
  • Refractory Tumor
  • Solid Tumor
  • Dendritic Cell Vaccine
  • +2 more
  • Kaohsiung, Taiwan
  • +2 more
Mar 2, 2023

Renal Cell Carcinoma Trial in Philadelphia (Pembrolizumab infusion, Lenvatinib tablet)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pembrolizumab infusion
  • Lenvatinib tablet
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Feb 8, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin Trial in Tampa (Lenvatinib Oral

Recruiting
  • Merkel Cell Carcinoma
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site Trial in San

Not yet recruiting
  • Neuroendocrine Tumors
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Feb 17, 2023

Melanoma Stage III Trial in North Sydney (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma Stage III
  • North Sydney, New South Wales, Australia
    Melanoma Institute Australia
Oct 26, 2022

Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult Trial in Taipei (Eribulin, Lenvatinib)

Active, not recruiting
  • Leiomyosarcoma
  • +3 more
  • Taipei, Taiwan
  • +1 more
Dec 27, 2022

Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Mucosal Melanoma
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Sep 15, 2022

Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma Trial in Miami (Lenvatinib, Pembrolizumab, Hypofractionated

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma
  • Miami, Florida
    University of Miami
Jan 10, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Prostate Cancer Metastatic, Neuroendocrine Tumors Trial in Atlanta, Ann Arbor (Pembrolizumab, Lenvatinib)

Recruiting
  • Prostate Cancer Metastatic
  • Neuroendocrine Tumors
  • Duarte, California
  • +2 more
Jan 18, 2023

Hepatocellular Carcinoma Trial in Houston (Lenvatinib, Transcatheter Arterial Chemoembolization)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Houston, Texas
    Houston Methodist Research Institute
Dec 10, 2021

Liver Tumor Trial in Guangzhou (TACE combined with Lenvatinib)

Recruiting
  • Liver Tumor
  • TACE combined with Lenvatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 23, 2022

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Biliary Tract Cancer Trial in Changchun (Lenvatinib, PD-1 inhibitors)

Recruiting
  • Biliary Tract Cancer
  • Changchun, Jilin, China
    Liu Bo
Aug 18, 2022

Efficacy of Lenvatinib in Differentiated Thyroid Cancer

Recruiting
  • Differentiated Thyroid Cancer
  • Gender
  • Rome, Italy
    Regina Elena National Cancer Institute
Mar 16, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Advanced Biliary Tract Carcinoma Trial in Shanghai (Pembrolizumab Injection [Keytruda], Lenvatinib Mesylate)

Recruiting
  • Advanced Biliary Tract Carcinoma
  • Pembrolizumab Injection [Keytruda]
  • Lenvatinib Mesylate
  • Shanghai, Shanghai, China
  • +1 more
Jul 19, 2022

Differentiated Thyroid Cancer, Advanced Cancer Trial in Boston (LENVATINIB)

Recruiting
  • Differentiated Thyroid Cancer
  • Advanced Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Feb 3, 2022